TP53 and ovarian carcinoma: Only one clinical trial (NCT02012192) in phase 1 and 2 has an inclusion criterion of mutp53 and investigates additive effects of ganetespib to paclitaxel on p53-mutated platinum-resistant ovarian cancers.